MX2021008920A - Un método de edición de genes. - Google Patents

Un método de edición de genes.

Info

Publication number
MX2021008920A
MX2021008920A MX2021008920A MX2021008920A MX2021008920A MX 2021008920 A MX2021008920 A MX 2021008920A MX 2021008920 A MX2021008920 A MX 2021008920A MX 2021008920 A MX2021008920 A MX 2021008920A MX 2021008920 A MX2021008920 A MX 2021008920A
Authority
MX
Mexico
Prior art keywords
gene editing
cell
methods
editing
gene
Prior art date
Application number
MX2021008920A
Other languages
English (en)
Inventor
David W Russell
Francoise J Haeseleer
Dhwanil Dalwadi
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of MX2021008920A publication Critical patent/MX2021008920A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En la presente se divulgan métodos para editar un gen en una célula que implican poner en contacto la célula con un modulador de horquilla de replicación, así como células editadas y sus métodos de uso.
MX2021008920A 2019-01-29 2020-01-29 Un método de edición de genes. MX2021008920A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962798357P 2019-01-29 2019-01-29
PCT/US2020/015550 WO2020160071A1 (en) 2019-01-29 2020-01-29 A method of gene editing

Publications (1)

Publication Number Publication Date
MX2021008920A true MX2021008920A (es) 2021-09-23

Family

ID=69726803

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008920A MX2021008920A (es) 2019-01-29 2020-01-29 Un método de edición de genes.

Country Status (9)

Country Link
US (1) US20220106596A1 (es)
EP (1) EP3918070A1 (es)
JP (1) JP2022518256A (es)
KR (1) KR20210121092A (es)
CN (1) CN113396220A (es)
BR (1) BR112021014645A2 (es)
CA (1) CA3126833A1 (es)
MX (1) MX2021008920A (es)
WO (1) WO2020160071A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL294014B2 (en) 2015-10-23 2024-07-01 Harvard College Nucleobase editors and their uses
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
CN111757937A (zh) 2017-10-16 2020-10-09 布罗德研究所股份有限公司 腺苷碱基编辑器的用途
WO2020191243A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
DE112021002672T5 (de) 2020-05-08 2023-04-13 President And Fellows Of Harvard College Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
AU2022206476A1 (en) * 2021-01-11 2023-07-20 President And Fellows Of Harvard College Prime editor variants, constructs, and methods for enhancing prime editing efficiency and precision
US20230340475A1 (en) * 2021-12-17 2023-10-26 University Of Massachusetts Oligonucleotides for mlh1 modulation
WO2024044850A1 (en) * 2022-08-30 2024-03-07 Feldan Bio Inc. Method and animal model for inducing bcc tumors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1398977B1 (it) * 2009-06-25 2013-03-28 Icgeb Agente anticancro specifico per i tumori cerebrali con meccanismo di soppressione di recq1
US10017825B2 (en) * 2014-11-17 2018-07-10 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for characterizing a DNA repair variant polypeptide
WO2017182783A2 (en) * 2016-04-18 2017-10-26 Phoremost Limited Inactivation of dna repair as an anticancer therapy
WO2017189894A1 (en) * 2016-04-27 2017-11-02 Yale University Multiplex genome engineering in eukaryotes
US20190169597A1 (en) * 2016-08-19 2019-06-06 Bluebird Bio, Inc. Genome editing enhancers
US20210198675A1 (en) * 2017-10-23 2021-07-01 Mark David Vincent Methods of treating cancer and/or enhancing sensitivity to cancer treatment by increasing tumor mutation burden or tumor indels

Also Published As

Publication number Publication date
EP3918070A1 (en) 2021-12-08
CN113396220A (zh) 2021-09-14
BR112021014645A2 (pt) 2022-01-11
JP2022518256A (ja) 2022-03-14
KR20210121092A (ko) 2021-10-07
US20220106596A1 (en) 2022-04-07
WO2020160071A1 (en) 2020-08-06
CA3126833A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
MX2021008920A (es) Un método de edición de genes.
EA201992795A1 (ru) Способ получения эукариотических клеток с отредактированной днк и набор, используемый в этом способе
WO2020082046A3 (en) Compositions and methods for expressing factor ix
WO2020081149A3 (en) Improved detection of nuclease edited sequences in automated modules and instruments
AU2016250905A8 (en) Generation of muscle-lineage cells from stem cells
GB2561496A (en) Devices and methods for simulating a function of a liver tissue
MA39959A (fr) Procédé de production de cellules progénitrices de foie adulte
GB2562396A (en) Devices for simulating a function of a liver tissue and methods of use and manufacturing thereof
KR20180084680A (ko) 식물 세포에서의 목적 단백질 발현을 위한 재조합 벡터
MX369514B (es) Metodo para producir celulas progenitoras hepaticas adultas.
EP3369810A4 (en) METHOD FOR PRODUCING CELL POPULATION WITH MESENCHYMAL STEM CELLS, MESENCHYMAL STEM CELLS, CELL POPULATION AND PHARMACEUTICAL COMPOSITION
AU2015311681A8 (en) Globin gene therapy for treating hemoglobinopathies
SG10201804330YA (en) Engineered high-affinity human t cell receptors
MX2021007474A (es) Homoserina deshidrogenasa modificada y procedimiento para la produccion de homoserina o l-aminoacido derivado de homoserina mediante el uso de la misma.
EP3263697A4 (en) Culture medium for culturing mesenchymal stem cell, method for culturing mesenchymal stem cell, and mesenchymal stem cell
WO2015075564A3 (en) System and method for making quantum dots
MX2020007591A (es) Homoserina deshidrogenasa modificada y procedimiento de produccion de homoserina o l-aminoacido derivado de homoserina mediante el uso de la misma.
EP3511410A4 (en) MEDIUM FOR THE CULTURE OF STEM CELLS, METHOD FOR THE CULTURE OF STEM CELLS, STEM CELL GROWTH PROMOTER AND COMPOSITION AND METHOD FOR THE PRODUCTION THEREOF
MX2017003651A (es) Métodos de establecimiento de bancos de células de densidad ultra-alta.
AR113150A1 (es) Producción mejorada de etanol libre de glicerol
WO2018049401A8 (en) PRIMARY LYMPHOCYTE B RESULTING FROM GENETIC EDITION AND METHODS OF PREPARATION AND USE
MX2022002527A (es) Metodos de preparacion de linfocitos t para la terapia con linfocitos t.
EP4029566A4 (en) SERUM-FREE MEDIUM NOT CONTAINING ALBUMINE SUITABLE FOR CULTIVATION OF HUMAN HEMATOPOIETIC STEM CELLS AND ALBUMIN-FREE CULTIVATION METHOD
EP3828262A4 (en) NOVEL RENAL PROGENITOR CELL MARKER AND METHOD OF RENAL PROGENITOR CELL CONCENTRATION USING THE SAME
EP4008774A4 (en) CELL CULTURE METHOD AND ITS APPLICATION BASED ON CONTINUOUS AND HIGH DENSITY INOCULATION